Geode Capital Management LLC Makes New Investment in CeriBell (NASDAQ:CBLL)

Geode Capital Management LLC bought a new stake in shares of CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 257,070 shares of the company's stock, valued at approximately $6,654,000. Geode Capital Management LLC owned about 0.72% of CeriBell as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. bought a new position in CeriBell during the 4th quarter valued at about $18,015,000. Franklin Resources Inc. bought a new position in CeriBell in the 4th quarter valued at $12,460,000. Emerald Advisers LLC purchased a new stake in CeriBell in the fourth quarter worth $3,126,000. Charles Schwab Investment Management Inc. bought a new stake in shares of CeriBell during the fourth quarter worth $2,500,000. Finally, JPMorgan Chase & Co. bought a new position in shares of CeriBell in the fourth quarter worth about $880,000.

CeriBell Stock Performance

Shares of CBLL traded up $0.17 during mid-day trading on Tuesday, hitting $16.36. The company's stock had a trading volume of 272,012 shares, compared to its average volume of 272,558. The company has a 50-day moving average price of $19.52. CeriBell has a 52-week low of $10.01 and a 52-week high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. Equities research analysts forecast that CeriBell will post -2.46 EPS for the current year.

Insider Activity at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 3,372 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $15.03, for a total transaction of $50,681.16. Following the completion of the sale, the chief executive officer now directly owns 743,079 shares of the company's stock, valued at approximately $11,168,477.37. This represents a 0.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 24,700 shares of company stock valued at $372,434 over the last quarter.

Analyst Ratings Changes

Several research firms have issued reports on CBLL. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH initiated coverage on CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $32.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.